Overview

Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD

Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
To assess genetic features and intraocular cytokine profiles of non-responders to anti-VEGF treatment of exudative age-related macular degeneration. Also to assess necessity and frequency of pro re nate medical re-treatment.
Phase:
Phase 4
Details
Lead Sponsor:
University of Cologne
Treatments:
Bevacizumab
Ranibizumab